Last reviewed · How we verify
BIIB033
At a glance
| Generic name | BIIB033 |
|---|---|
| Also known as | anti-LINGO-1 mAb, Anti-LINGO-1 antibody |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (PHASE2)
- Long-Term Assessment of Remyelinating Therapy (PHASE2)
- Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (PHASE2)
- Safety Study of BIIB033 in Subjects With Multiple Sclerosis (PHASE1)
- BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects (PHASE1)
- Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes (PHASE1)
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants (PHASE1)
- BIIB033 In Acute Optic Neuritis (AON) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |